Books and Book Chapters

      Analysis of Proteomic Data for Toxicological Applications

      Titz, B.; Schneider, T.; Elamin, A.; Martin, F.; Dijon, S.; Ivanov, N. V.; Hoeng, J.; Peitsch, M. C.

      Date published
      Sep 10, 2015
      DOI
      10.1007/978-1-4939-2778-4_11
      ISBN
      978-1-4939-2778-4
      Published in
      Computational Systems Toxicology
      Editors
      Hoeng, J.; Peitsch, M. C.
      Link to publication
      Topic
      Summary

      Toward a comprehensive characterization of toxicant responses, systems toxicology requires the integration of different data modalities. Proteomics approaches measure changes in the levels of proteins and their posttranslational modifications, which can closely reflect the biological effects of a toxicant. With a focus on mass spectrometry-based proteomics, we describe the isobaric tag-based approach for quantitative proteomics (iTRAQ® and TMT™) and describe computational approaches to derive biological/mechanistic insights. Specifically, we describe the generation and quantification of mass-spectrometry data and the identification of affected proteins, functional modules, and protein subnetworks. We illustrate these approaches using results from a 90-day rat inhalation toxicology study. Overall, we provide the foundation to employ quantitative proteomics within systems toxicology assessment strategies.

      Related Publications

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      Exposure to a Heated Tobacco Product Aerosol Is Associated with Lower Activity of Hepatic Cytochrome P450 Enzymes and Reduced Alteration in Clozapine Metabolism Than Exposure to Cigarette Smoke

      Pre-clinical Toxicology

      Evaluation of Chronic Inhalation Toxicity of E-Vapor Aerosols in an 18-Month Study in AJ Mice

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.